Industry Strength Score
24/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
EUPRAXIA PHARMACEUTICALS INC (EPRX) Stock Price & Overview
NASDAQ:EPRX • CA29842P1053
Current stock price
7.82 USD
+0.48 (+6.54%)
Last:
The current stock price of EPRX is 7.82 USD. Today EPRX is up by 6.54%. In the past month the price increased by 1.38%. In the past year, price increased by 83.27%.
EPRX Key Statistics
52-Week Range3.6669 - 9.32
Current EPRX stock price positioned within its 52-week range.
1-Month Range6.54 - 7.875
Current EPRX stock price positioned within its 1-month range.
- Market Cap
- 472.563M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.03
- Dividend Yield
- N/A
EPRX Stock Performance
Today
+6.54%
1 Week
+3.97%
1 Month
+1.38%
3 Months
-11.35%
Longer-term
6 Months +32.49%
1 Year +83.27%
2 Years +167.88%
3 Years N/A
5 Years N/A
10 Years N/A
EPRX Stock Chart
EPRX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to EPRX. When comparing the yearly performance of all stocks, EPRX is one of the better performing stocks in the market, outperforming 87.03% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
EPRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EPRX. No worries on liquidiy or solvency for EPRX as it has an excellent financial health rating, but there are worries on the profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
EPRX Earnings
Next Earnings DateMay 7, 2026
Last Earnings DateMar 12, 2026
PeriodQ4 / 2025
EPS Reported-$0.37
Revenue Reported
EPS Surprise -112.68%
Revenue Surprise %
EPRX Forecast & Estimates
11 analysts have analysed EPRX and the average price target is 11.76 USD. This implies a price increase of 50.36% is expected in the next year compared to the current price of 7.82.
Analysts
Analysts85.45
Price Target11.76 (50.38%)
EPS Next Y27.73%
Revenue Next YearN/A
EPRX Financial Highlights
Over the last trailing twelve months EPRX reported a non-GAAP Earnings per Share(EPS) of -1.03. The EPS decreased by -37.27% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-38.58M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.78% | ||
| ROE | -47.02% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-84.97%
Sales Q2Q%N/A
EPS 1Y (TTM)-37.27%
Revenue 1Y (TTM)N/A
EPRX Ownership
Ownership
Inst Owners30.93%
Shares60.43M
Float50.75M
Ins Owners16.03%
Short Float %5.06%
Short Ratio11.12
EPRX Industry Overview
EPRX operates in the Biotechnology sub-industry within the Health Care sector. This group contains 18 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
11/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
71%
Outperformed 71% of sub-industries
3 Month Rank
36%
Outperformed 36% of sub-industries
6 Month Rank
29%
Outperformed 29% of sub-industries
Industry Fundamentals & Breadth
- Members
- 18
- New Highs
- 0%
- New Lows
- 11.1%
- Average ROE
- 3.7%
- Average Profit Margin
- 3.1%
- Average Operating Margin
- 1.6%
- Average P/E
- 61.7
- Average Fwd P/E
- 9.1
- Average Debt/Equity
- 0.1
EPRX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.88 | 360.632B | ||
| AMGN | AMGEN INC | 15.16 | 182.426B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 159.919B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.94 | 107.655B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.82 | 72.562B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.34 | 40.188B | ||
| INSM | INSMED INC | N/A | 29.146B | ||
| BIIB | BIOGEN INC | 11.58 | 28.527B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.853B | ||
| NTRA | NATERA INC | N/A | 27.602B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.55 | 25.03B | ||
| INCY | INCYTE CORP | 10.43 | 19.722B | ||
| MRNA | MODERNA INC | N/A | 18.132B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EPRX
Company Profile
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia. The company went IPO on 2021-03-09. The firm is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The firm also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
Company Info
IPO: 2021-03-09
EUPRAXIA PHARMACEUTICALS INC
201-2067 Cadboro Bay Rd.
Victoria BRITISH COLUMBIA CA
Employees: 33
Phone: 12505903968
EUPRAXIA PHARMACEUTICALS INC / EPRX FAQ
Can you describe the business of EUPRAXIA PHARMACEUTICALS INC?
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia. The company went IPO on 2021-03-09. The firm is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The firm also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
What is the current price of EPRX stock?
The current stock price of EPRX is 7.82 USD. The price increased by 6.54% in the last trading session.
Does EPRX stock pay dividends?
EPRX does not pay a dividend.
How is the ChartMill rating for EUPRAXIA PHARMACEUTICALS INC?
EPRX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of EPRX stock?
EUPRAXIA PHARMACEUTICALS INC (EPRX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for EUPRAXIA PHARMACEUTICALS INC?
EUPRAXIA PHARMACEUTICALS INC (EPRX) has a market capitalization of 472.56M USD. This makes EPRX a Small Cap stock.